Diaminopropanol renin inhibitors

US7872028B2 · kind B2 · utility

Assignee

• Vitae Pharmaceuticals, LLC · US

Inventors

• John J. Baldwin · Gwynedd Valley, US
• David A. Claremon · Audubon, US
• Colin M. Tice · Ambler, US
• Salvacion Cacatian · Conshohocken, US
• Lawrence Wayne Dillard · Yardley, US
• Alexey V. Ishchenko · Somerville, US
• Jing Yuan · Lansdale, US
• Zhenrong Xu · Forest Park, US
• Gerard McGeehan · Chester Springs, US
• Wei Zhao · North Potomac, US
• Robert D. Simpson · Wilmington, US
• Suresh B. Singh · Kendall Park, US
• Patrick T. Flaherty · Pittsburgh, US

Key dates

• Filing date: Apr 5, 2007
• Grant date: Jan 18, 2011
• Expiry date: Apr 5, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Described are diaminopropanols of which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with elevated. levels of renin activity or in the treatment of aspartic protease mediated disorders. Also described is a method for the use of the diaminopropanols in ameliorating or treating renin related disorders in a subject in need thereof.